Clinical VNS: The Established FDA-Approved Foundation
Vagus nerve stimulation as a medical intervention has a 30-year clinical track record. The LivaNova (formerly Cyberonics) VNS Therapy System — an implanted pulse generator connected to the left cervical vagus nerve via a helical electrode — received FDA approval for adjunctive therapy in adults with drug-resistant partial-onset seizures in 1997, based on two pivotal randomized controlled trials (EO3 and EO5) that demonstrated statistically significant seizure frequency reduction versus low-stimulation control. By 2005, accumulated clinical data supported FDA approval for adjunctive treatment of chronic or recurrent depression in adults who had failed four or more antidepressant medications.
The epilepsy evidence base is the most robust: a 10-year observational study published in Neurology [1] showed that approximately 50% of patients achieve ≥50% seizure reduction with VNS over time, with response rates improving with longer duration of use — a pattern suggesting ongoing neuroplastic adaptation rather than a fixed pharmacological effect. A 2016 systematic review and meta-analysis published in Epilepsia [2] pooled data from over 5,500 patients across 78 studies and confirmed a median seizure reduction of 51% and a responder rate (≥50% seizure reduction) of 55%. These are real, durable, clinically meaningful outcomes in a population for whom conventional pharmacotherapy has failed.
The depression evidence is more complex. The initial FDA approval was controversial — the advisory panel voted against approval but FDA overrode the panel based on long-term data showing cumulative response over 1–2 years. A landmark long-term registry study [3] followed 795 treatment-resistant depression patients over 5 years, comparing VNS-augmented treatment to treatment-as-usual. The VNS group showed significantly better cumulative response (67.6% vs. 40.9%) and remission rates at 5 years — an effect that grew over time, consistent with the neuroplasticity hypothesis that VNS promotes synaptic changes in mood-regulating circuits via norepinephrine and serotonin projections from the vagally-connected locus coeruleus and raphe nuclei.
Tracey 2002 and the Inflammatory Reflex
The most scientifically consequential contribution to VNS research is arguably Kevin Tracey's discovery of the cholinergic anti-inflammatory pathway, first published in Nature in 2002. Tracey's group at the Feinstein Institutes demonstrated that vagal efferent fibers innervate immune organs — spleen, liver, gastrointestinal tract — and that vagal stimulation suppresses systemic inflammatory cytokine production (TNF-α, IL-1β, IL-6, IL-18) through activation of nicotinic acetylcholine receptors on macrophages in the spleen.
The mechanism — now called the "inflammatory reflex" — works as follows: the brain detects inflammatory signals via afferent vagal fibers and humoral cytokine signals; efferent vagal output to the spleen activates a splenic nerve → T cell → macrophage cholinergic cascade that suppresses TNF production. Tracey's subsequent work showed that electrical stimulation of the vagus nerve (independent of any pharmaceutical agent) could suppress TNF levels in rodent models of endotoxin-induced shock, sepsis, and rheumatoid arthritis — and that selective pharmacological blockade of cholinergic receptors reversed this protection.
This discovery shifted VNS research from a neurological niche into immunology, rheumatology, and critical care medicine — opening the possibility that an electrical device could treat inflammatory diseases through neural modulation rather than pharmacological immunosuppression.
Koopman 2016: The Rheumatoid Arthritis Milestone
The direct translation of Tracey's inflammatory reflex research to human clinical use came in Koopman et al. [4], published in the Proceedings of the National Academy of Sciences. This open-label proof-of-concept trial enrolled 17 patients with active rheumatoid arthritis who had failed methotrexate and at least one anti-TNF biologic — arguably the hardest-to-treat RA population.
Patients received an implanted vagal nerve stimulator with device-on and device-off periods in crossover fashion. The primary finding: VNS significantly reduced serum TNF-α levels during active stimulation, and 11 of 17 patients showed significant clinical improvement (ACR20 response) that was not observed during device-off periods. Mean disease activity score (DAS28) improved from 6.3 to 3.8 — a clinically meaningful reduction. Seven patients achieved ACR70 response (70% improvement in RA criteria), a stringent outcome rarely achieved in drug-resistant RA.
This was a small, open-label, proof-of-concept trial — not a definitive RCT — but it provided the first human evidence that the cholinergic anti-inflammatory pathway is modifiable with sufficient clinical impact to matter in a serious inflammatory disease. Larger sham-controlled trials are ongoing.
Transcutaneous VNS: The Non-Invasive Research Frontier
Implanted VNS requires surgery and carries procedural risks (vocal cord palsy, infection, lead fracture). Transcutaneous VNS (tVNS) delivers electrical stimulation to cutaneous branches of the vagus nerve — primarily the auricular branch (at the tragus or cymba conchae of the outer ear) or the cervical vagus through skin electrodes at the neck — without surgery. Whether tVNS activates the vagal pathway with comparable efficacy to implanted VNS is the central question, and the answer is probably "partially and with significant parameter dependence."
The PRESTO trial [5] randomized 243 episodic migraine patients to transcutaneous cervical VNS (gammaCore device, electroCore) or sham stimulation for acute migraine treatment. The primary endpoint — pain freedom at 30 minutes — was not significantly different between groups. However, a subgroup analysis showed benefit in patients without medication overuse, and a pre-specified secondary analysis showed significant benefit in pain relief (not freedom) at 60 minutes. The ACT2 trial [6] showed significant benefit for acute cluster headache with tVNS versus sham. gammaCore received FDA clearance for cluster headache in 2017 and migraine in 2018, making it the only FDA-cleared non-invasive VNS device.
Heart Rate Variability as a Vagal Tone Proxy
Heart rate variability (HRV) — the variation in time intervals between heartbeats — is the primary non-invasive proxy for vagal tone in both clinical research and consumer wearable contexts. The parasympathetic nervous system, primarily via the vagus nerve, controls cardiac beat-to-beat variability through modulation of the sinoatrial node; high vagal tone produces higher HRV, and HRV in the high-frequency band (0.15–0.40 Hz, reflecting respiratory sinus arrhythmia) is specifically attributed to cardiac vagal modulation.
HRV has clinical validity as a marker of cardiac autonomic function and is an independent predictor of cardiovascular mortality in several large cohort studies. Its use as a proxy for generalized vagal tone — and by extension, as a surrogate for the anti-inflammatory pathway — is more inferential. The vagus nerve has efferent fibers to the heart, lungs, gastrointestinal tract, and immune organs. Cardiac HRV reflects cardiac vagal tone specifically; whether it accurately represents vagal tone to the spleen and gut (the organs relevant to the anti-inflammatory reflex) is not established. Low HRV predicts worse outcomes in inflammatory diseases like rheumatoid arthritis and IBD, which is consistent with the hypothesis — but correlation is not a reliable mechanistic bridge.
- Elliott et al., 2011
- Englot et al.
- Aaronson et al., 2017, Journal of Clinical Psychiatry
- 2016
- Barbanti et al., 2019, Cephalalgia
- Silberstein et al., 2016, Headache